{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=57", "query": { "condition": "Relapse/Recurrence", "page": 57 }, "page_size": 10 }, "pagination": { "page": 57, "page_size": 10, "total_count": 3145, "total_pages": 315, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=58&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse%2FRecurrence&page=56&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-08T09:47:11.590Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02600897", "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2016-03-24", "completion_date": "2021-12-15", "has_results": true, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-11-08T09:47:11.590Z", "location_count": 8, "location_summary": "Marietta, Georgia • Detroit, Michigan • Columbia, Missouri + 4 more", "locations": [ { "city": "Marietta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Columbia", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02600897" }, { "nct_id": "NCT04150042", "title": "SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma Metastatic", "BRCA1 Mutation", "BRCA2 Mutation", "Pancreatic Acinar Cell Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer", "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Ductal Adenocarcinoma", "Breast Cancer Metastatic", "Breast Cancer Stage IV", "Pancreatic Cancer Stage IV", "HER2-negative Breast Cancer", "HER2 Negative Breast Carcinoma", "Adenocarcinoma of the Breast", "PALB2 Gene Mutation", "Pancreas Cancer, Metastatic", "Pancreas Cancer, Recurrent", "Pancreas Cancer", "Stage IV Pancreatic Cancer", "Stage 4 Pancreatic Cancer" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "Vitamin B12B", "type": "DRUG" }, { "name": "Vitamin C", "type": "DRUG" }, { "name": "Autologous Hematopoietic Stem Cells", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "General Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2021-01-13", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-11-08T09:47:11.590Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04150042" }, { "nct_id": "NCT03175224", "title": "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors", "Advanced Cancer", "Renal Cancer", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "NSCLC", "Lung Cancer", "Brain Tumor", "Glioblastoma Multiforme", "EGFR Gene Mutation", "MET Amplification", "HGF", "Thyroid Cancer", "Pancreatic Cancer", "Colon Cancer", "MET Alteration", "MET Fusion", "Exon 14 Skipping" ], "interventions": [ { "name": "APL-101 Oral Capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apollomics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 497, "start_date": "2017-09-27", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-11-08T09:47:11.590Z", "location_count": 6, "location_summary": "Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03175224" }, { "nct_id": "NCT03557970", "title": "JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Edicotinib", "type": "DRUG" }, { "name": "Pharmacokinetic Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-10-05", "completion_date": "2020-09-28", "has_results": true, "last_update_posted_date": "2021-12-02", "last_synced_at": "2026-11-08T09:47:11.590Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03557970" }, { "nct_id": "NCT00005786", "title": "Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Prolymphocytic Leukemia", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Splenic Marginal Zone Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2001-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-01", "last_synced_at": "2026-11-08T09:47:11.590Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005786" }, { "nct_id": "NCT05263492", "title": "Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Mismatch Repair-Proficient", "Recurrent Endometrial Cancer" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 4, "start_date": "2022-04-01", "completion_date": "2024-10-19", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-11-08T09:47:11.590Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05263492" }, { "nct_id": "NCT00834652", "title": "Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Depression" ], "interventions": [ { "name": "Sertraline", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "20 Years to 60 Years" }, "enrollment_count": 206, "start_date": "2007-09", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2018-09-10", "last_synced_at": "2026-11-08T09:47:11.590Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00834652" }, { "nct_id": "NCT00316836", "title": "Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "mammography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 554, "start_date": "2006-04", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2019-01-24", "last_synced_at": "2026-11-08T09:47:11.590Z", "location_count": 311, "location_summary": "Fairbanks, Alaska • Scottsdale, Arizona • Fort Smith, Arkansas + 222 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00316836" }, { "nct_id": "NCT00777244", "title": "Efficacy of Adjuvant Mitotane Treatment (ADIUVO)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Adrenocortical Carcinoma" ], "interventions": [ { "name": "MITOTANE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Turin, Italy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2008-04", "completion_date": "2020-12", "has_results": false, "last_update_posted_date": "2017-05-08", "last_synced_at": "2026-11-08T09:47:11.590Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Ann Arbor, Michigan", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00777244" }, { "nct_id": "NCT01946165", "title": "Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "LHRHa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 69, "start_date": "2013-10-31", "completion_date": "2017-07-28", "has_results": true, "last_update_posted_date": "2019-12-06", "last_synced_at": "2026-11-08T09:47:11.590Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01946165" } ] }